Company profile MORF
After 38 days of this quarter the interest is at 32.0. Based on that we can calculate that during remaining 53 days it will total up to 77.0. Morphic Holding expected interest is significantly lower compared to previous quarter (-66.1%) and same quarter last year (-55.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 100 | 55 -45.0% QoQ | 23 -58.2% QoQ | 20 -13.0% QoQ |
| 2020 | 32 -68.0% YoY 60.0% QoQ | 21 -61.8% YoY -34.4% QoQ | 22 -4.3% YoY 4.8% QoQ | 129 545.0% YoY 486.4% QoQ |
| 2021 | 184 475.0% YoY 42.6% QoQ | 116 452.4% YoY -37.0% QoQ | 61 177.3% YoY -47.4% QoQ | 27 -79.1% YoY -55.7% QoQ |
| 2022 | 143 -22.3% YoY 429.6% QoQ | 36 -69.0% YoY -74.8% QoQ | 126 106.6% YoY 250.0% QoQ | 21 -22.2% YoY -83.3% QoQ |
| 2023 | 174 21.7% YoY 728.6% QoQ | 165 358.3% YoY -5.2% QoQ | 133 5.6% YoY -19.4% QoQ | 227 981.0% YoY 70.7% QoQ |
| 2024 | 32 -81.6% YoY -85.9% QoQ | - | - | - |
The average 5 years interest of Morphic Holding was 7.1 per week. The last year interest of Morphic Holding compared to the last 5 years has changed by 81.27%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 191.18%.
There is not enough data for Morphic Holding MORF stock to provide analysis
There is not enough data for Morphic Holding MORF stock to provide correlation calculation
There is not enough data for Morphic Holding MORF stock to provide analysis
There is not enough data for Small-molecule integrin therapeutics to provide analysis
There is not enough data for Small-molecule integrin therapeutics to provide correlation calculation
There is not enough data for Small-molecule integrin therapeutics to provide analysis
After 15 days of this quarter the interest is at 68.0. Based on that we can calculate that during remaining 77 days it will total up to 417.0. autoimmune diseases treatment expected interest is significantly higher compared to same quarter last year (+127.9%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 228 |
| 2019 | 244 7.0% QoQ | 346 41.8% QoQ | 327 -5.5% QoQ | 314 37.7% YoY -4.0% QoQ |
| 2020 | 378 54.9% YoY 20.4% QoQ | 262 -24.3% YoY -30.7% QoQ | 245 -25.1% YoY -6.5% QoQ | 229 -27.1% YoY -6.5% QoQ |
| 2021 | 227 -39.9% YoY -0.9% QoQ | 233 -11.1% YoY 2.6% QoQ | 79 -67.8% YoY -66.1% QoQ | 168 -26.6% YoY 112.7% QoQ |
| 2022 | 283 24.7% YoY 68.5% QoQ | 379 62.7% YoY 33.9% QoQ | 180 127.8% YoY -52.5% QoQ | 183 8.9% YoY 1.7% QoQ |
| 2023 | 299 5.7% YoY 63.4% QoQ | 344 -9.2% YoY 15.1% QoQ | 319 77.2% YoY -7.3% QoQ | 68 -62.8% YoY -78.7% QoQ |
The average 5 years interest of autoimmune diseases treatment was 20.52 per week. The last year interest of autoimmune diseases treatment compared to the last 5 years has changed by 8.33%. The interest for autoimmune diseases treatment is seasonal. The last year interest is comparable to 5 years ago. It has changed only by -10.18%.
After 38 days of this quarter the interest is at 26.0. Based on that we can calculate that during remaining 53 days it will total up to 62.0. cardiovascular diseases treatment expected interest is significantly lower compared to previous quarter (-66.3%) and same quarter last year (-72.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 64 | 138 115.6% QoQ | 98 -29.0% QoQ | 114 16.3% QoQ |
| 2020 | 178 178.1% YoY 56.1% QoQ | 145 5.1% YoY -18.5% QoQ | 160 63.3% YoY 10.3% QoQ | 143 25.4% YoY -10.6% QoQ |
| 2021 | 215 20.8% YoY 50.3% QoQ | 247 70.3% YoY 14.9% QoQ | 99 -38.1% YoY -59.9% QoQ | 167 16.8% YoY 68.7% QoQ |
| 2022 | 175 -18.6% YoY 4.8% QoQ | 466 88.7% YoY 166.3% QoQ | 179 80.8% YoY -61.6% QoQ | 205 22.8% YoY 14.5% QoQ |
| 2023 | 223 27.4% YoY 8.8% QoQ | 388 -16.7% YoY 74.0% QoQ | 211 17.9% YoY -45.6% QoQ | 184 -10.2% YoY -12.8% QoQ |
| 2024 | 26 -88.3% YoY -85.9% QoQ | - | - | - |
The average 5 years interest of cardiovascular diseases treatment was 14.71 per week. The last year interest of cardiovascular diseases treatment compared to the last 5 years has changed by 21.82%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 82.67%.
There is not enough data for metabolic diseases treatment to provide analysis
There is not enough data for metabolic diseases treatment to provide correlation calculation
There is not enough data for metabolic diseases treatment to provide analysis
After 39 days of this quarter the interest is at 292.0. Based on that we can calculate that during remaining 52 days it will total up to 681.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 594 | 673 13.3% QoQ | 650 -3.4% QoQ | 813 25.1% QoQ |
| 2020 | 876 47.5% YoY 7.7% QoQ | 638 -5.2% YoY -27.2% QoQ | 543 -16.5% YoY -14.9% QoQ | 646 -20.5% YoY 19.0% QoQ |
| 2021 | 693 -20.9% YoY 7.3% QoQ | 683 7.1% YoY -1.4% QoQ | 628 15.7% YoY -8.1% QoQ | 742 14.9% YoY 18.2% QoQ |
| 2022 | 932 34.5% YoY 25.6% QoQ | 835 22.3% YoY -10.4% QoQ | 673 7.2% YoY -19.4% QoQ | 841 13.3% YoY 25.0% QoQ |
| 2023 | 1028 10.3% YoY 22.2% QoQ | 898 7.5% YoY -12.6% QoQ | 790 17.4% YoY -12.0% QoQ | 928 10.3% YoY 17.5% QoQ |
| 2024 | 292 -71.6% YoY -68.5% QoQ | - | - | - |
The average 5 years interest of fibrosis treatment was 58.99 per week. The last year interest of fibrosis treatment compared to the last 5 years has changed by 14.68%. The interest for fibrosis treatment is seasonal. The last year interest is quite higher compared to 5 years ago. It has increased by 15.72%.
After 34 days of this quarter the interest is at 422.0. Based on that we can calculate that during remaining 58 days it will total up to 1142.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 544 |
| 2019 | 956 75.7% QoQ | 951 -0.5% QoQ | 914 -3.9% QoQ | 975 79.2% YoY 6.7% QoQ |
| 2020 | 990 3.6% YoY 1.5% QoQ | 814 -14.4% YoY -17.8% QoQ | 936 2.4% YoY 15.0% QoQ | 929 -4.7% YoY -0.7% QoQ |
| 2021 | 869 -12.2% YoY -6.5% QoQ | 915 12.4% YoY 5.3% QoQ | 951 1.6% YoY 3.9% QoQ | 917 -1.3% YoY -3.6% QoQ |
| 2022 | 886 2.0% YoY -3.4% QoQ | 897 -2.0% YoY 1.2% QoQ | 859 -9.7% YoY -4.2% QoQ | 860 -6.2% YoY 0.1% QoQ |
| 2023 | 947 6.9% YoY 10.1% QoQ | 946 5.5% YoY -0.1% QoQ | 900 4.8% YoY -4.9% QoQ | 422 -50.9% YoY -53.1% QoQ |
The average 5 years interest of cancer treatment was 70.41 per week. The last year interest of cancer treatment compared to the last 5 years has changed by 0.24%. The interest for cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -1.58%.
There is not enough data for MORF-057 clinical trials to provide analysis
There is not enough data for MORF-057 clinical trials to provide correlation calculation
There is not enough data for MORF-057 clinical trials to provide analysis
After 38 days of this quarter the interest is at 138.0. Based on that we can calculate that during remaining 53 days it will total up to 330.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 167 | 326 95.2% QoQ | 215 -34.0% QoQ | 308 43.3% QoQ |
| 2020 | 459 174.9% YoY 49.0% QoQ | 370 13.5% YoY -19.4% QoQ | 390 81.4% YoY 5.4% QoQ | 320 3.9% YoY -17.9% QoQ |
| 2021 | 259 -43.6% YoY -19.1% QoQ | 491 32.7% YoY 89.6% QoQ | 362 -7.2% YoY -26.3% QoQ | 217 -32.2% YoY -40.1% QoQ |
| 2022 | 424 63.7% YoY 95.4% QoQ | 511 4.1% YoY 20.5% QoQ | 332 -8.3% YoY -35.0% QoQ | 464 113.8% YoY 39.8% QoQ |
| 2023 | 322 -24.1% YoY -30.6% QoQ | 559 9.4% YoY 73.6% QoQ | 427 28.6% YoY -23.6% QoQ | 521 12.3% YoY 22.0% QoQ |
| 2024 | 138 -57.1% YoY -73.5% QoQ | - | - | - |
The average 5 years interest of inflammatory bowel disease treatment was 29.05 per week. The last year interest of inflammatory bowel disease treatment compared to the last 5 years has changed by 19.9%. The interest for inflammatory bowel disease treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 53.64%.
There is not enough data for Next Gen a4ß7 Inhibitors to provide analysis
There is not enough data for Next Gen a4ß7 Inhibitors to provide correlation calculation
There is not enough data for Next Gen a4ß7 Inhibitors to provide analysis
There is not enough data for EGIDs treatment to provide analysis
There is not enough data for EGIDs treatment to provide correlation calculation
There is not enough data for EGIDs treatment to provide analysis
After 38 days of this quarter the interest is at 18.0. Based on that we can calculate that during remaining 53 days it will total up to 43.0. pouchitis treatment expected interest is significantly lower compared to previous quarter (-75.3%) and same quarter last year (-77.9%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 0 | 0 | 143 inf% QoQ | 54 -62.2% QoQ |
| 2020 | 225 inf% YoY 316.7% QoQ | 93 inf% YoY -58.7% QoQ | 145 1.4% YoY 55.9% QoQ | 75 38.9% YoY -48.3% QoQ |
| 2021 | 70 -68.9% YoY -6.7% QoQ | 178 91.4% YoY 154.3% QoQ | 192 32.4% YoY 7.9% QoQ | 137 82.7% YoY -28.6% QoQ |
| 2022 | 18 -74.3% YoY -86.9% QoQ | 210 18.0% YoY 1066.7% QoQ | 74 -61.5% YoY -64.8% QoQ | 71 -48.2% YoY -4.1% QoQ |
| 2023 | 195 983.3% YoY 174.6% QoQ | 22 -89.5% YoY -88.7% QoQ | 71 -4.1% YoY 222.7% QoQ | 174 145.1% YoY 145.1% QoQ |
| 2024 | 18 -90.8% YoY -89.7% QoQ | - | - | - |
The average 5 years interest of pouchitis treatment was 8.33 per week. The last year interest of pouchitis treatment compared to the last 5 years has changed by 7.32%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 56.57%.
There is not enough data for avß8 treatment to provide analysis
There is not enough data for avß8 treatment to provide correlation calculation
There is not enough data for avß8 treatment to provide analysis
After 38 days of this quarter the interest is at 113.0. Based on that we can calculate that during remaining 53 days it will total up to 271.0. Myelofibrosis treatment expected interest is significantly lower compared to previous quarter (-46.0%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 78 | 338 333.3% QoQ | 351 3.8% QoQ | 172 -51.0% QoQ |
| 2020 | 193 147.4% YoY 12.2% QoQ | 274 -18.9% YoY 42.0% QoQ | 438 24.8% YoY 59.9% QoQ | 138 -19.8% YoY -68.5% QoQ |
| 2021 | 43 -77.7% YoY -68.8% QoQ | 310 13.1% YoY 620.9% QoQ | 328 -25.1% YoY 5.8% QoQ | 347 151.4% YoY 5.8% QoQ |
| 2022 | 372 765.1% YoY 7.2% QoQ | 228 -26.5% YoY -38.7% QoQ | 439 33.8% YoY 92.5% QoQ | 287 -17.3% YoY -34.6% QoQ |
| 2023 | 401 7.8% YoY 39.7% QoQ | 375 64.5% YoY -6.5% QoQ | 390 -11.2% YoY 4.0% QoQ | 502 74.9% YoY 28.7% QoQ |
| 2024 | 113 -71.8% YoY -77.5% QoQ | - | - | - |
The average 5 years interest of Myelofibrosis treatment was 23.53 per week. The last year interest of Myelofibrosis treatment compared to the last 5 years has changed by 32.81%. The interest for Myelofibrosis treatment is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 73.03%.
After 38 days of this quarter the interest is at 70.0. Based on that we can calculate that during remaining 53 days it will total up to 168.0. solid tumor treatment expected interest is significantly higher compared to same quarter last year (+158.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 51 | 118 131.4% QoQ | 72 -39.0% QoQ | 22 -69.4% QoQ |
| 2020 | 50 -2.0% YoY 127.3% QoQ | 15 -87.3% YoY -70.0% QoQ | 75 4.2% YoY 400.0% QoQ | 77 250.0% YoY 2.7% QoQ |
| 2021 | 59 18.0% YoY -23.4% QoQ | 102 580.0% YoY 72.9% QoQ | 117 56.0% YoY 14.7% QoQ | 219 184.4% YoY 87.2% QoQ |
| 2022 | 128 116.9% YoY -41.6% QoQ | 29 -71.6% YoY -77.3% QoQ | 94 -19.7% YoY 224.1% QoQ | 71 -67.6% YoY -24.5% QoQ |
| 2023 | 65 -49.2% YoY -8.5% QoQ | 112 286.2% YoY 72.3% QoQ | 44 -53.2% YoY -60.7% QoQ | 168 136.6% YoY 281.8% QoQ |
| 2024 | 70 7.7% YoY -58.3% QoQ | - | - | - |
The average 5 years interest of solid tumor treatment was 6.76 per week. The last year interest of solid tumor treatment compared to the last 5 years has changed by 30.62%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 61.13%.
After 38 days of this quarter the interest is at 33.0. Based on that we can calculate that during remaining 53 days it will total up to 79.0. fibronectin integrin expected interest is significantly lower compared to previous quarter (-56.4%) and same quarter last year (-42.8%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 124 | 86 -30.6% QoQ | 111 29.1% QoQ | 276 148.6% QoQ |
| 2020 | 100 -19.4% YoY -63.8% QoQ | 144 67.4% YoY 44.0% QoQ | 138 24.3% YoY -4.2% QoQ | 163 -40.9% YoY 18.1% QoQ |
| 2021 | 58 -42.0% YoY -64.4% QoQ | 121 -16.0% YoY 108.6% QoQ | 131 -5.1% YoY 8.3% QoQ | 76 -53.4% YoY -42.0% QoQ |
| 2022 | 318 448.3% YoY 318.4% QoQ | 58 -52.1% YoY -81.8% QoQ | 141 7.6% YoY 143.1% QoQ | 261 243.4% YoY 85.1% QoQ |
| 2023 | 138 -56.6% YoY -47.1% QoQ | 119 105.2% YoY -13.8% QoQ | 247 75.2% YoY 107.6% QoQ | 181 -30.7% YoY -26.7% QoQ |
| 2024 | 33 -76.1% YoY -81.8% QoQ | - | - | - |
The average 5 years interest of fibronectin integrin was 11.63 per week. The last year interest of fibronectin integrin compared to the last 5 years has changed by 13.41%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by 14.9%.
There is not enough data for pulmonary hypertensive treatment to provide analysis
There is not enough data for pulmonary hypertensive treatment to provide correlation calculation
There is not enough data for pulmonary hypertensive treatment to provide analysis
There is not enough data for Janssen license agreement to provide analysis
There is not enough data for Janssen license agreement to provide correlation calculation
There is not enough data for Janssen license agreement to provide analysis
There is not enough data for Schrödinger collaboration agreement to provide analysis
There is not enough data for Schrödinger collaboration agreement to provide correlation calculation
There is not enough data for Schrödinger collaboration agreement to provide analysis
There is not enough data for Children's Medical Center license agreement. to provide analysis
There is not enough data for Children's Medical Center license agreement. to provide correlation calculation
There is not enough data for Children's Medical Center license agreement. to provide analysis